Some studies have suggested that a PSA nadir of >0.5 ng/mL after conventional dose RT with or without ADT is an important surrogate endpoint for prostate cancer-specific and all-cause mortality [5-7]. This evidence concerns the gene KLK3 and Familial prostate cancer.